X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs993360-   
Low Rs729259-   
Sales per share (Unadj.) Rs325.5107.0-  
Earnings per share (Unadj.) Rs39.3-27.0-  
Cash flow per share (Unadj.) Rs48.7-22.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.284.0-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.9 91.4%   
Avg P/E ratio x21.9-11.5 -190.9%  
P/CF ratio (eoy) x17.7-13.9 -127.7%  
Price / Book Value ratio x5.43.7 146.7%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,99152,238 465.2%   
No. of employees `00013.04.3 302.0%   
Total wages/salary Rs m16,4083,279 500.5%   
Avg. sales/employee Rs Th7,083.94,205.5 168.4%   
Avg. wages/employee Rs Th1,265.4763.7 165.7%   
Avg. net profit/employee Rs Th855.1-1,059.7 -80.7%   
INCOME DATA
Net Sales Rs m91,85718,054 508.8%  
Other income Rs m374126 295.5%   
Total revenues Rs m92,23018,181 507.3%   
Gross profit Rs m20,367-3,129 -651.0%  
Depreciation Rs m2,644779 339.3%   
Interest Rs m2,373489 485.3%   
Profit before tax Rs m15,724-4,271 -368.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827267 1,434.1%   
Profit after tax Rs m11,088-4,549 -243.7%  
Gross profit margin %22.2-17.3 -127.9%  
Effective tax rate %24.3-6.2 -389.5%   
Net profit margin %12.1-25.2 -47.9%  
BALANCE SHEET DATA
Current assets Rs m68,74613,223 519.9%   
Current liabilities Rs m27,0277,440 363.3%   
Net working cap to sales %45.432.0 141.8%  
Current ratio x2.51.8 143.1%  
Inventory Days Days85111 76.6%  
Debtors Days Days96124 77.1%  
Net fixed assets Rs m24,1327,708 313.1%   
Share capital Rs m28284 336.7%   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,92514,171 317.0%   
Long term debt Rs m45,3634,980 910.9%   
Total assets Rs m117,63926,770 439.4%  
Interest coverage x7.6-7.7 -98.6%   
Debt to equity ratio x1.00.4 287.3%  
Sales to assets ratio x0.80.7 115.8%   
Return on assets %11.4-15.2 -75.4%  
Return on equity %24.7-32.1 -76.9%  
Return on capital %19.1-19.8 -96.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,5741,541 426.6%  
From Investments Rs m-7,124-473 1,505.4%  
From Financial Activity Rs m5,4324,520 120.2%  
Net Cashflow Rs m1,9925,587 35.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.96 Rs / ZAR

Compare GLENMARK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: SANOFI INDIA  FRESENIUS KABI ONCO.  DR. DATSONS LABS  FDC LTD.  PIRAMAL ENTERPRISES  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS